Clinical Trial

Metastatic Nasopharyngeal Carcinoma

Name: Metastatic Nasopharyngeal Carcinoma — clinical trial record (NCT06886347)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated March 20, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.

Trial Details

NCT Number	NCT06886347
Lead Sponsor	Chen Xiaozhong
Conditions	Metastatic Nasopharyngeal Carcinoma
Enrollment	47 participants
Start Date	2023-07-07
Primary Completion	2026-04-01 (estimated)
Study Completion	2026-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-20